Results of a multicenter placebo-control
β
E. M. Lemmel; D. Brackertz; M. Franke; W. Gaus; P. W. Hartl; K. Machalke; H. Mie
π
Article
π
1988
π
Springer
π
English
β 660 KB
In a multicenter placebo-controlled double-blind randomized clinical study, 91 patients with rheumatoid arthritis were given 28 days' treatment with recombinant interferon-gamma (50 micrograms daily for 20 days, then 50 micrograms each second day up to day 28, given by subcutaneous injection). The a